Anti-Dementia Drugs and Co-Medication Among Patients with Alzheimer's Disease.

Background: There is a substantial risk of drug-interactions, adverse events, and inappropriate drug use (IDU) among frail Alzheimer's disease (AD) patients; however, there are few studies about co-medication and IDU in clinical settings. Objectives: To investigate anti-dementia drugs, associated ch...

Full description

Bibliographic Details
Published in:Drugs & Aging Vol. 31; no. 3; pp. 215 - 225
Main Authors: Fereshtehnejad, Seyed-Mohammad, Johnell, Kristina, Eriksdotter, Maria
Format: research tables/charts Journal Article
Published: Springer Nature Mar2014
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104034211&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 104034211
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1170229X
        C5B
      jtl: Drugs & Aging
      issn: 1170229X
      maglogo: N
    pubinfo:
      dt: Mar2014
      vid: 31
      iid: 3
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        104034211
        94694335
        10.1007/s40266-014-0154-8
        NLM24497071
        104034211
      ppf: 215
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Anti-Dementia Drugs and Co-Medication Among Patients with Alzheimer's Disease.
      aug:
        au:
          Fereshtehnejad, Seyed-Mohammad
          Johnell, Kristina
          Eriksdotter, Maria
        affil: Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society (NVS), Karolinska Institutet, Novum 5th floor 14186 Stockholm Sweden
      sug:
        subj:
          Alzheimer's Disease Drug Therapy
          Inappropriate Prescribing
          Polypharmacy
          Dementia Drug Therapy
          Cholinesterase Inhibitors
          Aspartic Acid Antagonists and Inhibitors
          Aspartic Acid Classification
          Human
          Cross Sectional Studies
          Clinical Assessment Tools
          Data Analysis Software
          T-Tests
          Multivariate Analysis
          Chi Square Test
      ab: Background: There is a substantial risk of drug-interactions, adverse events, and inappropriate drug use (IDU) among frail Alzheimer's disease (AD) patients; however, there are few studies about co-medication and IDU in clinical settings. Objectives: To investigate anti-dementia drugs, associated characteristics of cholinesterase inhibitors (ChEIs) and NMDA antagonists, co-medication, and IDU in a large population of outpatients with mild AD. Methods: In this cross-sectional analysis of medication characteristics, we analyzed data from the Swedish Dementia Quality Registry (SveDem) on 5,907 newly diagnosed AD patients who were registered in memory clinics. SveDem is a national quality registry in Sweden, which was established in 2007 to evaluate and improve dementia healthcare. Comparisons were performed concerning co-medications, use of ≥3 psychotropic drugs (IDU) and polypharmacy (≥5 drugs) based on anti-dementia treatment (ChEIs or NMDA antagonists). Information on baseline characteristics such as age, sex, living conditions, cognitive evaluation based on the Mini-Mental State Examination (MMSE) score, and diagnostic work-up was also evaluated. Results: The majority of the AD patients were in the mild stage of the disease. Overall, 4,342 (75.4 %) patients received any ChEI, 438 (7.6 %) used an NMDA antagonist and 74 (1.3 %) patients were treated with both. However, 907 (15.7 %) patients were not treated with any anti-dementia drug. While polypharmacy was seen in 33.5 % of patients, only 2.6 % concurrently used ≥3 psychotropic medications. Patients on ChEIs were significantly younger, had a higher MMSE score and were treated with a smaller number of medications (a proxy for overall co-morbidity). Co-medication with antipsychotics [3.3 vs. 7.6 %; adjusted odds ratio (OR) 0.55 (95 % CI 0.38-0.79)] and anxiolytics [5.8 vs. 10.9 %; adjusted OR 0.62 (95 % CI 0.46-0.84)] was significantly lower in the ChEI+ group than in those with no anti-dementia treatment. Conclusion: Patients taking ChEIs were treated with less antipsychotics and anxiolytics than those not taking ChEIs. More research is warranted to elucidate whether use of ChEIs in clinical practice can reduce the need for psychotropic drugs in AD patients.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N